Virtualization is a key technology used in a wide range of applications, from cloud computing to embedded systems. Over the last few years, mainstream computer architectures were extended with hardware virtualization support, giving rise to a set of virtualization technologies (e.g., Intel VT and Arm VE) that are now proliferating in modern processors and systems on chip (SoCs). In this article, we describe our work on hardware virtualization support in the RISC-V CVA6 core. Our contribution is multifold and encompasses architecture, microarchitecture, and design space exploration (DSE). In particular, we highlight the design of a set of microarchitectural enhancements [i.e., G-stage translation lookaside buffer (GTLB) and second-level TLB (L2 TLB)] to alleviate the virtualization performance overhead. We also perform a DSE and accompanying postlayout simulations (based on 22-nm FDX technology) to assess performance, power, and area (PPA). Furthermore, we map design variants on a field-programmable gate array (FPGA) platform (Genesys 2) to assess the functional performance–area tradeoff. Based on the DSE, we select an optimal design point for the CVA6 with hardware virtualization support. For this optimal hardware configuration, we collected functional performance results by running the MiBench benchmark on Linux atop Bao hypervisor for a single-core configuration. We observed a performance speedup of up to 16% (approximately 12.5% on average) compared with virtualization-aware nonoptimized design at the minimal cost of 0.78% in area and 0.33% in power. Finally, all works described in this article are publicly available and open-sourced for the community to further evaluate additional design configurations and software stacks.
1 January 2006 in Journal of Pharmaceutical and Biomedical Analysis
The determination of nimesulide in pharmaceutical formulation in the range of 10.38 to 39.47% m/m using near infrared spectroscopy and multivariate calibration based on partial least squares (PLS) and net analyte signal (NAS) was studied and validated by establishing its figures of merit. Suitable results were obtained, with limit of detection of 0.61%, limit quantification of 2.03%, accuracy estimated as root mean square error of prediction (RMSEP) of 1.05%, mean selectivity of 0.006, sensitivity of 0.004%, inverse analytical sensitivity of (0.20%)-1 and signal-to-noise ratio of 181. In addition, it was obtained relative errors lower than 10% that are acceptable values for quality control of this drug. These results indicate that the proposed method can be used in pharmaceutical industries as an alternative to standard analytical procedures.
1 February 2010 in Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy